Novaliq announces FDA approval of VEVYE™ (Cyclosporine Ophthalmic Solution) 0.1% for dry eye disease treatment
Novaliq GmbH, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, had announced that the U.S. Food and Drug Administration (FDA) has approved VEVYE™ (cyclosporine ophthalmic solution) 0.1% for the treatment of the signs and symptoms of dry eye disease.